Sackler Family Fortune Protected Under Purdue Pharma Bankruptcy Plan
The headquarters of Purdue Pharma, the pharmaceutical giant owned by the Sackler family, in Stamford, Connecticut. Image by Getty
Purdue Pharma has a bankruptcy plan that may ensure the Sackler family keeps their fortune.
Purdue, maker of the painkiller OxyContin, filed for Chapter 11 as it began the process of the settling several lawsuits, The Washington Post reported. The company asked the judge on Wednesday to temporarily pause the lawsuits racking up against the Sacklers, the family that owns it.
The Sacklers already agreed to a settlement with several states, which sued for their perpetuating role in the opioid crisis. If the judge doesn’t grant them protection, the company said the settlement deal may fall through.
State attorneys are incredulous, believing the Sacklers should be using their wealth — the state of Oregon believes they have taken about $10 billion out of the company, according to the Post — to combat the growing problem of opioid addiction.
Alyssa Fisher is a writer at the Forward. Email her at [email protected], or follow her on Twitter at @alyssalfisher
The Forward is free to read, but it isn’t free to produce
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
This is a great time to support independent Jewish journalism you rely on. Make a gift today!
— Rachel Fishman Feddersen, Publisher and CEO
Support our mission to tell the Jewish story fully and fairly.
Dive In
-
Fast Forward Trump says he and Netanyahu are ‘on the same side of every issue’ following talks on Iran, tariffs
-
Fast Forward California school board members accused of antisemitism during contentious meeting
-
Fast Forward Over 100 Chicago-area rabbis and cantors condemn Trump’s campus crackdown
-
Fast Forward An Israeli think tank used AI to analyze 4,400 American synagogue sermons. Here’s what it found.
Most Popular
- 1
Opinion The dangerous Nazi legend behind Trump’s ruthless grab for power
- 2
News Who is Alan Garber, the Jewish Harvard president who stood up to Trump over antisemitism?
- 3
News Student protesters being deported are not ‘martyrs and heroes,’ says former antisemitism envoy
- 4
Opinion What Jewish university presidents say: Trump is exploiting campus antisemitism, not fighting it
In Case You Missed It
-
Opinion How Trump’s attacks on the university target what has made America great for Jews
-
Culture This Jewish New Yorker survived the Holocaust and the Hungarian Revolution, and is still helping others today
-
Fast Forward Trump says he and Netanyahu are ‘on the same side of every issue’ following talks on Iran, tariffs
-
Fast Forward California school board members accused of antisemitism during contentious meeting
-
Shop the Forward Store
100% of profits support our journalism
Republish This Story
Please read before republishing
We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines.
You must comply with the following:
- Credit the Forward
- Retain our pixel
- Preserve our canonical link in Google search
- Add a noindex tag in Google search
See our full guidelines for more information, and this guide for detail about canonical URLs.
To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.